Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $92

Haemonetics Corporation

Haemonetics Corporation

HAE

0.00

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE: HAE) with a Neutral and raises the price target from $79 to $92.